Last Price$228.1(1.8%)
Market Cap$16.9B
(1.9%)
Peers median - 3.2%
9.6%
Peers median - 11.3%
11.3%
Peers median - 29.8%
18.6%
Peers median - 7.5%
Competing with WST
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$16.9B | 6.1 | $152.8 33.0% overvalued | (36.3%) | $2,893.1M | $276.4M | (1.9%) | 9.6% | 34.6% | 18.6% | 11.3% | |
$207.3B | 6.9 | $106.1 81.3% overvalued | 41.5% | $8,352.1M | $1,077.2M | 17.2% | 12.9% | 67.5% | 26.8% | 0.0% | |
$66.3B | 6.1 | $262.7 15.0% undervalued | (1.4%) | $20.6B | $2,936.0M | 5.9% | 14.2% | 59.4% | 5.4% | 55.9% | |
$46.6B | 6.4 | $81.3 13.6% overvalued | 9.9% | $9,926.1M | $608.0M | 3.6% | 6.1% | 55.6% | 9.1% | 23.8% | |
$34.6B | 7.6 | $190.6 18.2% overvalued | 29.9% | $4,926.8M | $1,388.4M | 12.9% | 28.2% | 57.9% | 32.9% | 16.0% | |
$18.6B | 5.8 | $92.7 1.2% undervalued | (10.8%) | $3,895.4M | $288.1M | 8.4% | 7.4% | 62.8% | 5.9% | 32.0% | |
$17.9B | 4.7 | $52.7 51.1% undervalued | (16.2%) | $12.9B | $566.0M | (14.0%) | 4.4% | 37.1% | (1.5%) | 191.5% | |
$14.7B | 7.3 | $131.7 108.2% undervalued | (15.2%) | $4,038.9M | $1,135.5M | 1.8% | 28.1% | 56.2% | 13.2% | 1.0% | |
$10.4B | 5.2 | $139.9 26.6% overvalued | 50.3% | $2,094.4M | $145.3M | 2.3% | 6.9% | 48.0% | (14.8%) | 69.2% | |
$9,757.8M | 6.5 | $174.5 19.0% undervalued | 4.2% | $3,582.9M | $349.2M | 2.7% | 9.7% | 48.7% | 12.0% | 27.7% | |
$8,979.7M | 5.9 | $29.8 80.8% overvalued | (20.6%) | $616.0M | $131.3M | (8.0%) | 21.3% | 46.9% | (1.2%) | 33.3% |
Compare WST Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
West Pharmaceutical Services, Inc.WST
5.8x
(1.9%)
(15.5%)
17.0%
Median Peer Set
5.1x
3.4%
23.0%
10.2%
Alcon Inc.ALC
5.0x
8.5%
182.9%
10.3%
AptarGroup, Inc.ATR
2.9x
2.7%
30.2%
10.5%
Baxter International Inc.BAX
2.3x
(69.5%)
(100.0%)
(6.9%)
Becton, Dickinson and CompanyBDX
4.1x
4.2%
18.3%
8.4%
The Cooper Companies, Inc.COO
5.4x
8.4%
32.2%
10.1%
Hologic, Inc.HOLX
3.2x
(0.0%)
81.1%
19.6%
Intuitive Surgical, Inc.ISRG
24.3x
17.2%
27.7%
27.8%
Masimo CorporationMASI
5.2x
0.6%
(42.5%)
4.0%
Repligen CorporationRGEN
14.4x
(21.1%)
(80.9%)
5.6%
ResMed Inc.RMD
7.1x
10.9%
13.4%
21.8%
Compare WST Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does West Pharmaceutical Services, Inc. (WST) revenue growth compare to peers and the industry?
West Pharmaceutical Services, Inc. (WST) revenue growth is (1.9%), compared to the peers' median of 3.2%.
2. How does West Pharmaceutical Services, Inc. (WST) Free Cash Flow (FCF) margin compare to peers and the industry?
West Pharmaceutical Services, Inc. (WST) FCF margin is 9.6%, compared to the peers' median of 11.3%.
3. How does West Pharmaceutical Services, Inc. (WST) Total Debt to Equity ratio compare to peers and the industry?
West Pharmaceutical Services, Inc. (WST) Total Debt to Equity ratio is 11.3%, compared to the peers' median of 29.8%.
4. How does West Pharmaceutical Services, Inc. (WST) ROIC (Return on Invested Capital) compare to peers and the industry?
West Pharmaceutical Services, Inc. (WST) ROIC is 18.6%, compared to the peers' median of 7.5%.